Am J Hematol. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases.
Arch Pathol Lab Med. Syndromes of thrombotic microangiopathy. Warkentin TE. HIT: more than just heparin. HIT paradigms and paradoxes. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. Use of homologous platelet survival in differential diagnoses of chronic thrombocytopenia in childhood. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia.
Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia.
Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. The American Society of Hematology evidence-based practice guideline for immune thrombocytopenia. Platelet transfusion: a systematic review of the clinical evidence.
Transfusion [ Google Scholar ]. American Hospitals Association. Fast facts on US hospitals. Available at: www. Accessed December Adjustments for center in multicenter studies: an overview.
Ann Intern Med. Association between race and age in survival after trauma. JAMA Surg. Software MAD. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Laboratory abnormalities in thrombotic thrombocytopenic purpura. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura.
J Clin Apher. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. American College of Chest Physicians. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of patients. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia with thrombosis: a clinical dilemma ameliorated by novel use of plasmapheresis.
Int J Hematol. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. International consensus report on the investigation and management of primary immune thrombocytopenia. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later.
Acta Haematol. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. J Clin Exp Hematop.
Am J Epidemiol. A model for clinical research, education and patient care. Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Support Center Support Center. External link. Please review our privacy policy. An adverse event was defined as any complication including seizures, cerebrovascular accident, bleeding, thrombosis, myocardial infarction or death for any reason within 30 days from the PLT transfusion.
Results: Our cohort included patients with the clinical diagnosis of TTP. The patients who received PLT transfusion were not different from those who did not in terms of age, gender, race, haematocrit, PLT count, creatinine, LDH and complications.
Major bleed 9. View Large. Table 2 —Platelet transfusions among ITP patients with bleeding complications.
Type of complication. All ages. Age 0—17 years. Major bleed Volume , Issue Previous Article Next Article. View Metrics. Cited By Web Of Science 2. Email alerts Article Activity Alert. Latest Issue Alert. Close Modal.
0コメント